Global News

Clinical research and the Zika virus

Monday, May 9, 2016

The Pulse on Global Trials by Matthew Howes

Zika, the latest public health threat, has been hot media buzz for a while now. What began in early 2015 in Brazil has spread to neighboring parts of Latin America, as well as islands in the Pacific. In January 2016, the World Health Organization (WHO) said the virus was likely to spread throughout most of the Americas by the end of the year. Will public awareness and fear of the disease spreading translate into rapid action on the part of clinical research? Probably not.

[Read More]

Epizyme appoints Matthew Ros chief operating officer

Friday, May 6, 2016

Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.

[Read More]

Precision for Medicine acquires Applied Immunology

Thursday, May 5, 2016

Precision for Medicine, part of the Precision Medicine Group, has acquired Applied Immunology, which focuses in the creation and delivery of custom cell-based and immunoassay solutions. Applied Immunology supports innovative and targeted therapeutics developers across all areas, ranging from immuno-oncology to rare diseases to biosimilars from research to post-approval. Applied Immunology’s client base includes some of the most pioneering new venture-backed startups, along with many major global pharmaceutical firms. 

[Read More]

Formula Pharmaceuticals appoints Malcolm K. Brenner to scientific advisory board

Thursday, May 5, 2016

Formula Pharmaceuticals has appointed Dr. Malcolm K. Brenner, founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease.

[Read More]

WAVE, Pfizer partner on metabolic diseases

Thursday, May 5, 2016

WAVE Life Sciences has entered into a research, license and option agreement with Pfizer for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE’s proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer’s hepatic targeting technology for enhanced delivery to the liver.

[Read More]

Veeva Vault updates Veeva Vault

Thursday, May 5, 2016

Veeva Systems has released the updated version of Veeva Vault, version 14. The Veeva Vault platform and suite of enterprise applications empower life sciences companies to streamline their business processes across an increasingly broad ecosystem of internal and external stakeholders.

[Read More]

Biogen to spin off hemophilia business

Tuesday, May 3, 2016

Biogen intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise.

[Read More]